: A new generation of ulcerative colitis drugs is in development. Will they be blockbusters for Lilly and Pfizer?

  • Written by MarketWatch
  • Published in Economics
Pfizer’s promising ulcerative colitis treatment could generate $1.9 billion in sales by 2030. Lilly’s got a drug in development, too.
...

Read more from our friends at MarketWatch